PEDIATRICS Vol. 101 No. 5 May 1998, pp. 851-855
Received Jun 21, 1996; accepted Sep 17, 1997.
From the Divisions of Newborn Medicine (Joint Program in Neonatology), Respiratory Diseases and Genetics, Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Objectives. To assess the application of DNA-based cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation analysis as a primary cystic fibrosis (CF) diagnostic test in preterm and term newborns and infants for whom the quantitative pilocarpine iontophoresis test (QPIT) cannot be used.
Design. Retrospective survey.
Setting. DNA Diagnostic Laboratory, Children's Hospital, Boston, Massachusetts. Buccal cell DNA samples were received from inpatients, outpatients, and three neonatal intensive care units.
Outcome Measure. Detection of at least 1 of 12 CFTR mutations.
Patients. Between November 1, 1992, and April 30, 1994, 28 newborns and infants under 12 months of age at risk for CF had CFTR DNA
mutation analysis performed because a sweat chloride (SC) value could
not be obtained. QPIT was either not performed (infant weight <2 kg,
QPIT not available at site of hospitalization, or infant not accessible
to QPIT laboratory) or was inconclusive (sweat volume <75 mg or
indeterminate SC [
40, <60 mEq/L]). The postnatal age at time of
testing ranged from 1 day to 11 months, and gestational age at birth
from 25 to 40 weeks.
Results. Six (21%) of 28 infants with unobtainable or indeterminate QPIT had 1 or 2 CFTR mutations detected. Immediate CF diagnosis by direct detection of 2 CFTR mutations was made in 5 of these 6 patients. Definitive CF diagnosis in the infant with 1 CFTR mutation was delayed until an elevation in SC could be documented. The patients with no CFTR mutations detected had a low likelihood of CF.
Conclusions. For infants in whom CF is suspected but QPIT cannot be obtained, buccal cell DNA-based CFTR mutation analysis can be used as a rapid, noninvasive primary diagnostic test. This simple mode of DNA collection may aid in the diagnosis of other inherited disorders in newborns.
Key words: cystic fibrosis, CFTR, sweat chloride, pilocarpine iontophoresis, DNA mutation analysis, premature newborn.
This article has been cited by other articles:
![]() |
S. M. Beckett, S. J. Laughton, L. D. Pozza, G. B. McCowage, G. Marshall, R. J. Cohn, E. Milne, and L. J. Ashton Buccal Swabs and Treated Cards: Methodological Considerations for Molecular Epidemiologic Studies Examining Pediatric Populations Am. J. Epidemiol., May 15, 2008; 167(10): 1260 - 1267. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Batal, M.-B. Ericsoussi, J. E. Cluette-Brown, B. P. O'Sullivan, S. D. Freedman, J. E. Savaille, and M. Laposata Potential Utility of Plasma Fatty Acid Analysis in the Diagnosis of Cystic Fibrosis Clin. Chem., January 1, 2007; 53(1): 78 - 84. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. I. Kaye and and the Committee on Genetics Newborn Screening Fact Sheets Pediatrics, September 1, 2006; 118(3): e934 - e963. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Stene, D. Hongve, P. Magnus, K. S. Ronningen, and G. Joner Acidic Drinking Water and Risk of Childhood-Onset Type 1 Diabetes Diabetes Care, September 1, 2002; 25(9): 1534 - 1538. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Stene, P. Magnus, K. S. Ronningen, and G. Joner Diabetes-Associated HLA-DQ Genes and Birth Weight Diabetes, December 1, 2001; 50(12): 2879 - 2882. [Abstract] [Full Text] [PDF] |
||||